| Name | Title | Contact Details |
|---|
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers. The highly fragmented global Healthcare IT and EMR market is expected to grow by 15% to $10 billion by 2015. Ambient believes there is a significant opportunity in this growing market to implement analytics based dashboard tools to reduce errors and improve efficiency. Our goal is supported by a $16 million CMS grant to deploy Ambient’s AWARE program in 3 hospitals starting September 2013. This software platform can be used in any data intensive hospital unit and is the perfect combination of “Big Data” and “Analytics”. Our analytical tools and suggested care checklists are unique to the current healthcare IT market. Ambient Clinical Analytics is supported financially by software license fees, SaaS, Cloud, and system integration revenue.
Riverland Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Ferriday, LA. To find more information about Riverland Medical Center, please visit www.riverlandmedical.com
iCardiac Technologies is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Rochester, NY. To find more information about iCardiac Technologies, please visit www.icardiac.com
In 1972 HOPE, Inc and ARC Children`s Program consolidated into one single service organization. In 1976 this organization became Sunflower Diversified Services. And now each year, this organization serves over 125 adults, 36 to 42 Pre-school age children and 120 to 140 infants from birth to 3 years old.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.